Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 57 clinical trials
featured
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or

refractory follicular lymphoma
rituximab
bendamustine
measurable disease
obinutuzumab
  • 575 views
  • 24 Aug, 2021
  • 11 locations
featured
A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab,or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

The purpose of this study is to evaluate the safety and tolerability of INCB050465 when combined with rituximab, bendamustine and rituximab, or ibrutinib in participants with relapsed or

lymphoma
lymphomas
b-cell lymphoma
  • 72 views
  • 14 Dec, 2020
  • 21 locations
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell

rituximab
acalabrutinib
bendamustine
cyclin d1
  • 1279 views
  • 17 Sep, 2021
  • 253 locations
A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment

The purpose of this study is to compare ofatumumab & chlorambucil (O-Chl) versus ofatumumab & bendamustine (O-B) in patients with Chronic Lymphocytic Leukaemia who are considered not fit

rituximab
anemia
bendamustine
ofatumumab
chlorambucil
  • 436 views
  • 08 Nov, 2020
  • 1 location
Treatment With Lenalidomide Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma

Define maximum tolerable dose of the combination lenalidomide, bendamustine, prednisone.

lenalidomide
cancer
refractory multiple myeloma
prednisone
  • 64 views
  • 08 Nov, 2020
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

, researchers hope to determine whether the combined drugs are successful in treating HCL. Pentostatin and bendamustine are two anti-cancer drugs that have been used to treat different kinds of blood

  • 0 views
  • 12 Sep, 2021
  • 1 location
Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL

Phase II study for treatment of patients with relapsed or primary refractory aggressive B- cell NHL and anthracycline chemotherapy pretreatment, who received or did not qualify for autologous stem cell transplantation.

rituximab
cell transplantation
bendamustine
salvage therapy
anthracyclines
  • 16 views
  • 07 Nov, 2020
  • 1 location
Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients

A randomized phase III multicenter trial assessing efficacy and toxicity of a combination of Rituximab and Lenalidomide (R2) vs Rituximab alone as maintenance after chemoimmunotherapy with Rituximab-chemotherapy (R-CHT) for relapsed/refractory FL patients not eligible for autologous transplantation (ASCT)

rituximab
platelet count
bendamustine
tumor burden
lenalidomide
  • 37 views
  • 06 Sep, 2021
  • 37 locations
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression free survival.

rituximab
chemoimmunotherapy
bendamustine
venetoclax
measurable disease
  • 1222 views
  • 20 Aug, 2021
  • 243 locations
Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma

This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma

  • 40 views
  • 10 Sep, 2021
  • 122 locations